Oyster Point Pharma, Inc. (OYST) CEO Jeffrey Nau on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 11/08/20
Oyster Point Pharma to Report Third Quarter 2020 Financial Results on November 5, 2020GlobeNewsWire • 10/29/20
Oyster Point Pharma Announces Board of Directors Leadership Changes and New Appointment as the Company Advances into Next Phase of GrowthGlobeNewsWire • 10/08/20
Oyster Point Pharma to Present at the Morgan Stanley Virtual 18th Annual Global Healthcare ConferenceGlobeNewsWire • 09/11/20
Oyster Point Pharma, Inc. (OYST) CEO Jeffrey Nau on Q2 2020 Results - Earnings Call TranscriptSeeking Alpha • 08/08/20
Oyster Point Pharma Reports Second Quarter 2020 Financial Results and Recent Business HighlightsGlobeNewsWire • 08/05/20
Oyster Point Pharma to Report Second Quarter 2020 Financial Results on August 5, 2020GlobeNewsWire • 07/31/20
Oyster Point Pharma Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional SharesGlobeNewsWire • 05/19/20
Oyster Point Pharma, Inc. (OYST) CEO Jeffrey Nau on Q1 2020 Results - Earnings Call TranscriptSeeking Alpha • 05/11/20
Oyster Point Pharma Announces Positive Results in ONSET-2 Phase 3 Trial of OC-01 Nasal Spray for the Treatment of the Signs and Symptoms of Dry Eye DiseaseGlobeNewsWire • 05/11/20
Oyster Point Pharma Completes Enrollment in ONSET-2 Pivotal Phase 3 Clinical Trial of OC-01 Nasal Spray for Dry Eye Disease and Provides COVID-19 Business UpdateGlobeNewsWire • 03/30/20
Oyster Point Pharma, Inc. (OYST) CEO Jeffrey Nau on Q4 2019 Results - Earnings Call TranscriptSeeking Alpha • 03/01/20
Oyster Point Pharma Announces Addition to the Russell 2000®, Russell 3000® and Russell Microcap® IndexesGlobeNewsWire • 12/23/19